Vertex Pharmaceuticals (NQ:VRTX)

502.87 -0.63 (-0.13%)

Delayed Quote Updated: 3:04 PM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2

...

18 19 20 21 22 23 24 25 26

...

77 78 Next >

Vertex Pharmaceuticals Shares Are Up Today: What's Going On? ↗

January 31, 2025

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trading higher Friday following two major developments that strengthen its position in both pain management and gene therapy.

Via Benzinga

Charter Communications Posts Upbeat Earnings, Joins Atlassian, SkyWest, Eastman Chemical, AbbVie And Other Big Stocks Moving Higher On Friday ↗

January 31, 2025

Via Benzinga

Friday's pre-market session: top gainers and losers in the S&P500 index ↗

January 31, 2025

Get insights into the top gainers and losers in the S&P500 index of Friday's pre-market session.

Via Chartmill

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England

January 31, 2025

From Vertex Pharmaceuticals

Via Business Wire

Vertex Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (21 Ratings) ↗

January 30, 2025

Via Benzinga

Is Vertex Pharmaceuticals Stock a Buy in 2025? ↗

January 26, 2025

Via The Motley Fool

Vertex Pharmaceuticals Jumps On FDA Approval For Non-Opioid Painkiller ↗

January 30, 2025

The first-in-class drug had suffered a setback in December.

Via Investor's Business Daily

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

January 30, 2025

From Vertex Pharmaceuticals Incorporated

Via Business Wire

This Everest Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday ↗

January 30, 2025

Via Benzinga

Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10

January 27, 2025

From Vertex Pharmaceuticals Incorporated

Via Business Wire

How Is The Market Feeling About Vertex Pharmaceuticals? ↗

January 15, 2025

Via Benzinga

Forecasting The Future: 23 Analyst Projections For Vertex Pharmaceuticals ↗

January 10, 2025

Via Benzinga

Got $5,000? 2 Top Healthcare Stocks to Buy in 2025 and Hold Forever. ↗

January 25, 2025

Via The Motley Fool

2 Healthcare Stocks You Can Buy Right Now Before They Surge Even Higher ↗

January 24, 2025

Via The Motley Fool

MaxCyte: Building the Future of Cell and Gene Therapy Innovation

January 23, 2025

MaxCyte's proprietary Flow Electroporation technology enables companies like Vertex and CRISPR Therapeutics to get FDA approved for their gene-editing therapy.

Via MarketBeat

Got $1,500? 3 Healthcare Stocks to Buy and Hold Forever ↗

January 21, 2025

Via The Motley Fool

8 Health Care Stocks Whale Activity In Today's Session ↗

January 20, 2025

Via Benzinga

3 Unstoppable Stocks to Buy in 2025 ↗

January 18, 2025

Via The Motley Fool

HHS Challenges Vertex Over Fertility Services Program Tied To Casgevy Gene Therapy, Says Company Is 'Grasping at Straws' ↗

January 16, 2025

HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its gene-editing therapy for sickle cell disease.

Via Benzinga

Vertex's Pain Drug: Big Pharma's Next Major Success?

January 16, 2025

Vertex Pharmaceuticals' innovative pain drug holds significant potential, positioning the company for substantial growth in the expanding market.

Via MarketBeat

Should You Buy Vertex Pharmaceuticals Stock Hand Over Fist Before Jan. 30? ↗

January 16, 2025

Via The Motley Fool

Here's How Much $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today ↗

January 14, 2025

Via Benzinga

Vertex Pharmaceuticals Sets Sight on Expanding Portfolio with Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials ↗

January 14, 2025

Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and strengthens its global drug pipeline.

Via Benzinga

Meet the Innovative Growth Stock That Could Rocket 114% to 152% Higher in 2025, According to a Couple of Wall Street Analysts ↗

January 14, 2025

Via The Motley Fool

My 3 Highest-Conviction Growth Stocks to Buy in 2025 ↗

January 13, 2025

Via The Motley Fool

Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings

January 12, 2025

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Pfizer Is 'Too Low To Sell,' Jim Cramer Says: Recommends Nvidia For Robotics Exposure ↗

January 10, 2025

Pfizer stock is down more than 7% over the past year. The pharma giant is in talks to extend its collaboration with an AI start-up.

Via Benzinga

Topics Artificial Intelligence

Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore

January 10, 2025

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore

January 10, 2025

From Zai Lab Limited

Via Business Wire

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗

January 09, 2025

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.

Via Investor's Business Daily

Topics Artificial Intelligence Government

< Previous 1 2

...

18 19 20 21 22 23 24 25 26

...

77 78 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.